November 13, 2007 - Cardiogenesis Corp., a leading developer of surgical products for transmyocardial revascularization (TMR), announced that the FDA has granted marketing approval for its PEARL (Port Enabled Angina Relief using Laser) 5.0 Robotic Delivery System, allowing TMR treatment to be performed entirely endoscopically.
